Even if the number of patients included in this genetic analysis is small and prevents any conclusion, the mechanisms of resistance to BTKi could be different in HCL and in CLL in which mutations in BTK and in PCLγ2 have been documented in patients with CLL progressing after ibrutinib treatment (78). Here, BTK is linked to B-cell chronic lymphocytic leukemia.